Trial Profile
A Single/Repeat Dose Study With Three Oral Formulations of Firategrast (Immediate Release Tablet, Modified Release Tablet, and Naso-gastric Infusion) in Healthy Male Volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Nov 2023
Price :
$35
*
At a glance
- Drugs Firategrast (Primary) ; Firategrast (Primary)
- Indications Multiple sclerosis
- Focus Pharmacokinetics
- Sponsors GSK
- 01 May 2022 According to a Form 6-K, 2022, company SEC filing, GlaxoSmithKline has changed its name to GSK.
- 14 Nov 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 17 Aug 2011 New trial record